GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » Pretax Margin %

SpringWorks Therapeutics (SpringWorks Therapeutics) Pretax Margin % : -416.00% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. SpringWorks Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-87.39 Mil. SpringWorks Therapeutics's Revenue for the three months ended in Mar. 2024 was $21.01 Mil. Therefore, SpringWorks Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was -416.00%.

The historical rank and industry rank for SpringWorks Therapeutics's Pretax Margin % or its related term are showing as below:

SWTX' s Pretax Margin % Range Over the Past 10 Years
Min: -5968.5   Med: -3049.36   Max: -130.21
Current: -1281.78


SWTX's Pretax Margin % is ranked worse than
76.46% of 1028 companies
in the Biotechnology industry
Industry Median: -155.98 vs SWTX: -1281.78

SpringWorks Therapeutics Pretax Margin % Historical Data

The historical data trend for SpringWorks Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpringWorks Therapeutics Pretax Margin % Chart

SpringWorks Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial - -130.21 - - -5,968.50

SpringWorks Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1,731.63 -416.00

Competitive Comparison of SpringWorks Therapeutics's Pretax Margin %

For the Biotechnology subindustry, SpringWorks Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpringWorks Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where SpringWorks Therapeutics's Pretax Margin % falls into.



SpringWorks Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

SpringWorks Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-325.104/5.447
=-5,968.50 %

SpringWorks Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-87.385/21.006
=-416.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpringWorks Therapeutics  (NAS:SWTX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


SpringWorks Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Washington Boulevard, Stamford, CT, USA, 06902
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Executives
Tai-an Lin officer: Chief Scientific Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz director, 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl officer: Chief People Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy officer: Chief Medical Officer 368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam director, officer: Chief Executive Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith officer: See Remarks C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess officer: Head of Research & Development C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto director, 10 percent owner C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar officer: Chief Commercial Officer C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris officer: Chief Business Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902

SpringWorks Therapeutics (SpringWorks Therapeutics) Headlines